Provided by Tiger Trade Technology Pte. Ltd.

Omeros

10.60
+0.15501.48%
Volume:147.57K
Turnover:1.56M
Market Cap:751.19M
PE:-5.27
High:10.70
Open:10.33
Low:10.30
Close:10.44
52wk High:17.65
52wk Low:2.95
Shares:70.90M
Float Shares:64.55M
Volume Ratio:0.48
T/O Rate:0.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0098
EPS(LYR):-2.6958
ROE:-576.33%
ROA:-32.41%
PB:-3.41
PE(LYR):-3.93

Loading ...

Hims & Hers, Salesforce, Omeros, United Airlines, And Sea Ltd: Why These 5 Stocks Are On Investors' Radars Today

Benzinga_recent_news
·
Oct 16, 2025

Sector Update: Health Care Stocks Advance Late Afternoon

MT Newswires Live
·
Oct 16, 2025

Gold Gains Over 1%; Abbott Shares Fall After Q3 Results

Benzinga
·
Oct 16, 2025

Needham Sticks to Its Hold Rating for Omeros (OMER)

TIPRANKS
·
Oct 16, 2025

Omeros Rocks 151%. Novo Nordisk Signs up to $2.1 Billion Licensing Deal with Omeros in Rare Disease Push

Reuters
·
Oct 15, 2025

Omeros price target raised to $20 from $9 at H.C. Wainwright

TIPRANKS
·
Oct 15, 2025

Omeros Corporation : H.c. Wainwright Raises Target Price to $20 From $9

THOMSON REUTERS
·
Oct 15, 2025

Omeros Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Oct 15, 2025

Unusually active option classes on open October 15th

TIPRANKS
·
Oct 15, 2025

Omeros Corp Shares More Than Double After up to $2.1 Billion Licensing Deal With Novo Nordisk, Last up 176%

THOMSON REUTERS
·
Oct 15, 2025

Omeros Corp Shares Nearly Triple Premarket After up to $2.1 Billion Licensing Deal With Novo Nordisk

THOMSON REUTERS
·
Oct 15, 2025

Omeros Signs Major Deal with Novo Nordisk

TIPRANKS
·
Oct 15, 2025

Omeros up 124% at $9.20 after entering license agreement for zaltenibert

TIPRANKS
·
Oct 15, 2025

Omeros Shares Surge Pre-Bell After Asset Purchase, License Deal With Novo Nordisk

MT Newswires Live
·
Oct 15, 2025

Omeros Corporation announces asset purchase and license agreement with Novo Nordisk for MASP3 inhibitor zaltenibart

Reuters
·
Oct 15, 2025

BRIEF-Novo Nordisk Signs Up To $2.1 Bln Asset Purchase & License Deal With Omeros

Reuters
·
Oct 15, 2025

Novo Nordisk: Co & Omeros Enter Asset Purchase & License Deal for Omeros’ Clinical-Stage Masp-3 Inhibitor Zaltenibart

THOMSON REUTERS
·
Oct 15, 2025

Novo Nordisk: Under Deal Terms, Co to Be Granted Exclusive Global Rights to Develop, Commercialise Zaltenibart in All Indications

THOMSON REUTERS
·
Oct 15, 2025

Novo Nordisk: Omeros Eligible to Receive $340 Mln in Upfront & Near-Term Milestone Payments, up to $2.1 Bln

THOMSON REUTERS
·
Oct 15, 2025

Novo Nordisk: Omeros Retains Some Rights to Its Preclinical Masp-3 Programmes Unrelated to Zaltenibart

THOMSON REUTERS
·
Oct 15, 2025